Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



FDA approves second gene therapy for cancer

19 October 2017

By Jennifer Willows

Appeared in BioNews 923

The US Food and Drug Administration (FDA) have approved the world's second gene therapy to target blood cancer.

The therapy, Yescarta, is intended for adult patients with large B-cell lymphoma for whom the conventional types of treatment have failed.

'Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,' said FDA commissioner Scott Gottlieb. 'Gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer.'

Large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma, which account for four percent of cancers in the US. Currently, up to half of all patients with large B-cell lymphoma relapse or become resistant to treatments, which may include chemotherapy and stem cell transplants.

The new gene therapy, Yescarta, is a 'living drug' made from the patient's own immune cells. Like the first gene therapy for blood cancer, Kymriah (see BioNews 916), creating Yescarta requires extracting the patient's T-cells and modifying them to include a gene coding for chimeric antigen receptor (CAR). The so-called CAR-T cells are transfused back into the patient where they are better able to target and destroy cancer cells.

The drug was originally developed at the National Cancer Institute by a team led by Dr Steven Rosenberg. Yescarta was acquired by Kite Pharma in 2012, which was bought by pharma giant Gilead in August.

The FDA reported that 100 patients treated with Yescarta had a 51 percent complete remission rate in a multicentre clinical trial.

However, like other CAR-T therapies (see BioNews 917), the treatment carries the risk of life-threatening side effects, including high fever, low blood pressure, lung congestion and neurological problems. As a result the FDA requires hospitals and clinics to have special certification to provide the therapy.

'We will soon release a comprehensive policy to address how we plan to support the development of cell-based regenerative medicine. That policy will also clarify how we will apply our expedited programs to breakthrough products that use CAR-T cells and other gene therapies,' said Gottlieb.

The New York Times reported the treatment takes about 17 days overall to be developed and available for a patient.

'I believe this treatment approach brings hope to many patients, but one thing to consider is cost,' said Dr Michaela Almgren of the University of South Carolina College of Pharmacy.

Gilead have priced Yescarta at $373,000 for a one-time dose.


27 November 2017 - by Theofanis Michailidis 
The US Food and Drug Administration (FDA) is taking an active stance against the use of 'do it yourself' gene therapy kits...
20 November 2017 - by Martha Henriques 
The US Food and Drug Administration has announced a fast-track review process for gene therapies and other regenerative medicine treatments...

16 October 2017 - by Rikita Patel 
The US Food Drug and Administration advisory committee has backed the use of gene therapy to treat a hereditary disease for the first time...
11 September 2017 - by Ebtehal Moussa 
Two trials assessing gene therapy for blood cancer have been put on hold by the US Food and Drug Administration, following a patient fatality...
04 September 2017 - by Meetal Solanki 
The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation